Handok Begins Exclusive Sales Of Abbott's Lipidil In The Korean Market

Handok has announced that the company has initiated the commercialisation of Lipidil in Korea. Lipidil is a hyperlipidemia treatment developed by Abbott. Under an exclusive agreement with Abbott, Handok will have the rights to distribute, sell, and promote two Lipidil products, Lipidil Supra and Lipidil NT, in the local Korean market.

Lipidil contains fenofibrate as its active ingredient and is a popular fibrate-based treatment for hyperlipidemia in global and Korean markets. Lipidil Supra is the original fenofibrate product from Abbott, while Lipidil NT, which has been reimbursed since January 2023, offers patients the added convenience of administration regardless of meals.

Handok’s Senior Vice President Kim Yoon-mi at the ETC division said in a statement, "Leveraging our success in the diabetes business, Handok is expanding its competitiveness into hypertension and hyperlipidemia. By introducing Lipidil, we are broadening our product portfolio in the chronic disease sector, enabling us to provide comprehensive treatment solutions while strengthening our leadership in this market through synergies with our existing products."

The addition to Handok's portfolio strengthens its presence in the market of chronic disease therapies. This will broaden the company's scope in diabetes, hypertension, and hyperlipidemia.

Handok has consistently expanded its offerings in chronic disease management. Its diabetes portfolio includes treatments like Amaryl, Tenelia, and Lantus, alongside blood glucose monitoring devices like Barozen. In 2024, the company introduced Aprovasc, a hypertension treatment co-developed with Sanofi, and deepened its partnership by co-marketing Sanofi's Approval and CoAprovel.